oral paclitaxel + fruquintinib

Oral paclitaxel + fruquintinib is a combination therapy being investigated for the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. It consists of an oral solution of paclitaxel, a microtubule-stabilizing agent, and fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR-1, -2, and -3). While the Phase 3 FRUTIGA trial established the efficacy of intravenous paclitaxel in combination with fruquintinib as a second-line treatment for gastric cancer in China, this specific combination utilizes an oral formulation of paclitaxel to improve patient convenience and potentially alter the safety profile. The combination aims to inhibit both tumor cell proliferation and angiogenesis by targeting the mitotic machinery and the vascular supply of the tumor.

Brand names

FruzaqlaElunate

Other names

fruquintinib plus oral paclitaxeloral paclitaxel solution + fruquintinib